1. FDA understandable in 30 seconds

2. What kind of organization is the type of influence?

The drug discovery and DDS articles will not make medicines yourself, unlike companies. instead ofWhat pathways will affect the industry?is divided into four types.

3. What is DDS?

The FDA is mainly responsible for the examination of new drugs.CDERComment On June 30, 2003, the examination of mono。nal antibody and the。eutic protein was transferred from CBER to CDER. Vac s and blood preparations are affected by CBER Facts。

2025-2026 modality

CDER’s new drug list includes modalities used in the technical commentary of this series. The following classification was written by the name of the active ingredient in the list (-deruxtecan-vedotin=ADC, -siran=siRNA, -rsen=antis ). The calculation of this paper。

4. Scope of influence (authorization and region)

5. Companies and organizations involved

6. Future Prospects

7. Glossary

8. Source

1. FDA　FDA at a G The 2025 accounting year's budget is about $70 billion and the breakdown of financial resources, about 78% of the 20,593 FTE, the budget of human medicine, and the active ingredient manufacturer is located in the U.S. and headquarters. https://www.fda.gov/media/154548/download
2. FDA　FDA History (The current regulatory work began in 1906, and the current name was in 1930). https://www.fda.gov/about-fda/fda-history
3. FDA　Transfer of Regulatory Biological Products to CDER https://www.fda.gov/combination-products/jurisdictional-information/transfer-therapeutic-biological-products-center-drug-evaluation-and-research
4. FDA（CDER）　Novel Drug Approvals for 2025 https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
5. FDA（CDER）　Healthancing Health Through Innovation: New Drug Approvals 2025 (35 new active ingredients, 12 biologics, 58 combined with CBER, 70% first approval in the United States, the number of uses of the rapid system, 6 months prioritization, 10 months, 123 items, Zosduri and Wegovy tablets) https://www.fda.gov/media/190705/download
6. FDA（CDER）　Novel Drug Approvals for 2026 https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
7. FDA　Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
8. FDA　Commissioner's National Priority Voucher (CNPV) Pilot Program (Unsubscribed in June 2025, five national priorities, one to two months, non-transferable) https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program
9. FDA　rugdance "Clinical Pharmacology Considerations for Antibody-Drug Conjugates" (March 2024, Final Edition, CDER・CBER). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry
10. FDA　icaldance "Clinical Pharmacology Considerations for the Development of Oligonucleotide Theticseutics" (Final Edition, CDER, June 2024). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics
11. FDA　Draftancedance “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction
12. FDA　Prescription Drug User Fee Amendments (Updated every 5 years, PDUFA VII 2023 to 2027, PDUFA VIII 2028 to 2032) https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments
13. FDA　FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Paintextex Pharmaceuticals https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
14. FDA　FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor In。tors Authorized by Sanofi, Orphan Drug Fast Track). https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors
15. ICH　Members & Ob。s (Regulators at the time of establishment: EC, Europe/FDA, United States/MHLW/PMDA, Japan) PA, China) https://www.ich.org/page/members-observers

9. Response table of claims and sources

Last Updated:September 26, 2026/Troy Technical
FDA official website, annual report, guidance press release, and ICH official website. This is an interpretation that reads from primary information. This article does not recommend certain medicines.